Skip to main content

Table 3 Comparison of the PR3-ANCA-positive and negative groups in the active phase

From: Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis

 

PR3-ANCA positive

(n = 85)

PR3-ANCA negative

(n = 74)

P value

Age, mean ± SD (years)

40.8 ± 17.2

46.6 ± 16.7

0.034

Sex, male/female

45 (52.9%)/40 (47.1%)

39 (52.7%)/35 (47.3%)

1

BMI, mean ± SD (kg/m2)

22.4 ± 3.2

22.3 ± 3.7

0.89

History of smoking

24 (28.2%)

28 (37.8%)

0.24

Current alcohol consumption

22 (25.9%)

19 (25.7%)

1

Age at onset, mean ± SD (years)

35.3 ± 16.9

38.2 ± 16.0

0.27

Disease duration, median (range), years

3.0 (0–8)

6.0 (1–13)

0.083

Type

  

0.28

Extensive

62 (72.9%)

45 (60.8%)

 

Left-sided

17 (20.0%)

22 (29.7%)

 

Proctitis

6 (7.1%)

7 (9.5%)

 

Frequency of defecation per day, median (range)

5 (3–8)

4 (2–7)

0.11

Bloody stool

54 (63.5%)

41 (55.4%)

0.33

CRP, median (range), mg/dL

0.32 (0.06–1.39)

0.15 (0.04–0.87)

0.15

Alb, median (range), g/dL

4.0 (3.2–4.4)

4.2 (3.8–4.4)

0.089

Plt, median (range), × 104/μL

31.2 (25.4–40.2)

29.9 (22.6–35.5)

0.20

Fecal hemoglobin, median (range), ng/mL

1703 (264–6054)

1158 (137–4675)

0.278

CMV infection

5 (5.9%)

4 (5.4%)

1

MES, median (range)

3 (2–3)

2 (1–3)

0.032

Matts grade, median (range)

4 (3–5)

3 (3–4)

0.013

  1. SD, standard deviation; BMI, body mass index; CRP, C-reactive protein; Alb, albumin; Plt, platelet; CMV, cytomegalovirus; MES, Mayo Endoscopic Subscore